(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 January 2011 (20.01.2011)

PCT

(10) International Publication Number
WO 2011/006497 A1

(51) **International Patent Classification**:
C07K 14/605 (2006.01) ***A61P 5/48*** (2006.01)
A61K 38/26 (2006.01)

(21) **International Application Number**:
PCT/DK2010/000099

(22) **International Filing Date**:
24 June 2010 (24.06.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

09251780.4	13 July 2009 (13.07.2009)	EP
61/225,080	13 July 2009 (13.07.2009)	US
10157240.2	22 March 2010 (22.03.2010)	EP
PA 2010 00412	10 May 2010 (10.05.2010)	DK

(71) **Applicant** *(for all designated States except US)*: **ZEALAND PHARMA A/S** [DK/DK]; Smedeland 36, DK-2600 Glostrup (DK).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **RIBER, Ditte** [DK/DK]; Degnemose Allé 64, DK-2700 Brønshøj (DK). **MEIER, Eddi** [DK/DK]; Bringebakken 88, DK-3500 Værløse (DK). **DAUGAARD, Jens, Rosengren** [DK/DK]; Bakkevej 6, DK-2830 Virum (DK). **SKOVGAARD, Marie** [DK/DK]; Strandvejen 75A, 3. th., DK-2100 Copenhagen Ø (DK). **TOLBORG, Jakob, Lind** [DK/DK]; Bispevangen 35, DK-2750 Ballerup (DK). **KAMPEN, Gita** [DK/DK]; Gærdebuen 18, DK-2850 Nærum (DK). **BÆK, Camilla, Ærteberg** [DK/DK]; Kirkeltevej 18, DK-3450 Allerød (DK).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2011/006497 A1

(54) **Title**: ACYLATED GLUCAGON ANALOGUES

(57) **Abstract**: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.